A vs AZTA
A: A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical diagnostics laboratories worldwide. AZTA: Azenta is a provider of life sciences solutions focused on automated sample management and genomic services for research and clinical development.
Side-by-side fundamentals
| Metric | A | AZTA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $137.89 | $27.52 | |
| Market cap as of 2026-07-30 | $38.9B | $1.3B | |
| P/E as of 2026-07-30 | 27.99 | n/a | |
| PEG as of 2026-07-30 | 3.24 | -0.04 | AZTA lower |
| Net margin as of 2026-07-30 | +19.6% | -29.9% | A higher |
| Gross margin as of 2026-07-30 | +52.9% | +43.9% | A higher |
| Operating margin as of 2026-07-30 | +21.5% | -28.9% | A higher |
| ROE as of 2026-07-30 | +20.8% | -10.7% | A higher |
| ROA as of 2026-07-30 | +11.1% | -8.8% | A higher |
| Debt / equity as of 2026-07-30 | 0.47 | 0.00 | AZTA lower |
| Revenue growth (YoY) as of 2026-07-30 | +9.1% | -5.9% | A higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +2.2% | AZTA higher |
| Dividend yield as of 2026-07-30 | +0.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | 1 | A higher |
| Beta as of 2026-07-30 | 1.23 | 1.37 | |
| 1-year return as of 2026-07-27 close | +14.7% | -20.1% | A higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.